DRUG
Denosumab treatment in osteoporotic patients
To examine the effectiveness of denosumab in osteoporotic patients
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
Status
Unknown
Phase
Phase 4
Enrollment
100
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
It has not been well known about the changes of bone metabolic markers, bone mineral density and other bone-related markers after teriparatide and/or denosumab treatment in Japanese osteoporotic patients.
Interventions
Treatment arms and agents.
DRUG
Teriparatide treatment in osteoporotic patients
To examine the effectiveness of teriparatide in osteoporotic patients
DRUG
Denosumab and teriparatide treatment in osteoporotic patients
To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
Timeline
From registration to results.
First posted
Jun 5, 2014
Study start
May 2014
Primary completion
May 2015
Study completion
Nov 2022
Results posted
Not reported
Registry updated
Oct 22, 2020
Outcomes
What the study measures.
Primary outcomes
Changes of bone mineral density
Time frame · every 4-6 months
Bone mineral density will be examined every 4-6 months to evaluate the suitability of the drug.
Secondary outcomes
Changes of bone turnover markers
Time frame · every 3-6 months
Bone turnover markers will be examined every 3-6 months to evaluate the suitability of the drug.
Eligibility
Who can take part.
- Minimum age
- 1 Year
- Maximum age
- 120 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: * Osteoporotic patients Exclusion Criteria: * none
Study locations
1 registered sites.
Japan. Showing up to 24 locations stored in the fast local snapshot.
Yukio Nakamura
Matsumoto, Nagano, Japan
Publications
Results and literature.
Related trials
More studies on Teriparatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.